SHIH, David J.H., Paul A. NORTHCOTT, Marc REMKE, Andrey KORSHUNOV, Vijay RAMASWAMY, Marcel KOOL, Betty LUU, Yuan YAO, Xin WANG, Adrian M. DUBUC, Livia GARZIA, John PEACOCK, Stephen C. MACK, Xiaochong WU, Adi ROLIDER, Sorana A. MORRISSY, Florence M.G. CAVALLI, David T.W. JONES, Karel ZITTERBART, Claudia C. FARIA, Ulrich SCHULLER, Leoš KŘEN, Toshihiro KUMABE, Teiji TOMINAGA, Young Shin RA, Miklos GARAMI, Peter HAUSER, Jennifer A. CHAN, Shenandoah ROBINSON, László BOGNÁR, Almos KLEKNER, Ali G. SAAD, Linda M. LIAU, Steffen ALBRECHT, Adam FONTEBASSO, Giuseppe CINALLI, Pasqualino De ANTONELLIS, Massimo ZOLLO, Michael K. COOPER, Reid C. THOMPSON, Simon BAILEY, Janet C. LINDSEY, Concezio DI ROCCO, Luca MASSIMI, Erna M.C. MICHIELS, Stephen W. SCHERER, Joanna J. PHILLIPS, Nalin GUPTA, Xing FAN, Karin M. MURASZKO, Rajeev VIBHAKAR, Charles G. EBERHART, Maryam FOULADI, Boleslaw LACH, Shin JUNG, Robert J. WECHSLER-REYA, Michelle FEVRE-MONTANGE, Anne JOUVET, Nada JABADO, Ian F. POLLACK, William A. WEISS, Ji-Yeoun LEE, Byung-Kyu CHO, Seung-Ki KIM, Kyu-Chang WANG, Jeffrey R. LEONARD, Joshua B. RUBIN, Carmen de TORRES, Cinzia LAVARINO, Jaume MORA, Yoon-Jae CHO, Uri TABORI, James M. OLSON, Amar GAJJAR, RogerJ. PACKER, Stefan RUTKOWSKI, Scott L. POMEROY, Pim J. FRENCH, Nanne K. KLOOSTERHOF, Johan M. KROS, Erwin G. VAN MEIR, Steven C. CLIFFORD, Franck BOURDEAUT, Olivier DELATTRE, Francois F. DOZ, Cynthia E. HAWKINS, David MALKIN, Wieslawa A. GRAJKOWSKA, Marta PEREK-POLNIK, Eric BOUFFET, James T. RUTKA, Stefan M. PFISTER and Michael D. TAYLOR. Cytogenetic Prognostication Within Medulloblastoma Subgroups. Journal of clinical oncology. United States: American Society of Clinical Oncology, 2014, vol. 32, No 9, p. 886-896. ISSN 0732-183X. Available from: https://dx.doi.org/10.1200/JCO.2013.50.9539.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Cytogenetic Prognostication Within Medulloblastoma Subgroups
Authors SHIH, David J.H. (124 Canada), Paul A. NORTHCOTT (276 Germany), Marc REMKE (124 Canada), Andrey KORSHUNOV (276 Germany), Vijay RAMASWAMY (124 Canada), Marcel KOOL (276 Germany), Betty LUU (124 Canada), Yuan YAO (124 Canada), Xin WANG (124 Canada), Adrian M. DUBUC (124 Canada), Livia GARZIA (124 Canada), John PEACOCK (124 Canada), Stephen C. MACK (124 Canada), Xiaochong WU (124 Canada), Adi ROLIDER (124 Canada), Sorana A. MORRISSY (124 Canada), Florence M.G. CAVALLI (124 Canada), David T.W. JONES (276 Germany), Karel ZITTERBART (203 Czech Republic, guarantor, belonging to the institution), Claudia C. FARIA (124 Canada), Ulrich SCHULLER (276 Germany), Leoš KŘEN (203 Czech Republic, belonging to the institution), Toshihiro KUMABE (392 Japan), Teiji TOMINAGA (392 Japan), Young Shin RA (410 Republic of Korea), Miklos GARAMI (348 Hungary), Peter HAUSER (348 Hungary), Jennifer A. CHAN (124 Canada), Shenandoah ROBINSON (840 United States of America), László BOGNÁR (348 Hungary), Almos KLEKNER (348 Hungary), Ali G. SAAD (840 United States of America), Linda M. LIAU (840 United States of America), Steffen ALBRECHT (124 Canada), Adam FONTEBASSO (124 Canada), Giuseppe CINALLI (380 Italy), Pasqualino De ANTONELLIS (380 Italy), Massimo ZOLLO (380 Italy), Michael K. COOPER (840 United States of America), Reid C. THOMPSON (840 United States of America), Simon BAILEY (826 United Kingdom of Great Britain and Northern Ireland), Janet C. LINDSEY (826 United Kingdom of Great Britain and Northern Ireland), Concezio DI ROCCO (380 Italy), Luca MASSIMI (380 Italy), Erna M.C. MICHIELS (528 Netherlands), Stephen W. SCHERER (124 Canada), Joanna J. PHILLIPS (840 United States of America), Nalin GUPTA (840 United States of America), Xing FAN (840 United States of America), Karin M. MURASZKO (840 United States of America), Rajeev VIBHAKAR (840 United States of America), Charles G. EBERHART (840 United States of America), Maryam FOULADI (840 United States of America), Boleslaw LACH (124 Canada), Shin JUNG (410 Republic of Korea), Robert J. WECHSLER-REYA (840 United States of America), Michelle FEVRE-MONTANGE (250 France), Anne JOUVET (250 France), Nada JABADO (124 Canada), Ian F. POLLACK (840 United States of America), William A. WEISS (840 United States of America), Ji-Yeoun LEE (410 Republic of Korea), Byung-Kyu CHO (410 Republic of Korea), Seung-Ki KIM (410 Republic of Korea), Kyu-Chang WANG (410 Republic of Korea), Jeffrey R. LEONARD (840 United States of America), Joshua B. RUBIN (840 United States of America), Carmen de TORRES (724 Spain), Cinzia LAVARINO (724 Spain), Jaume MORA (724 Spain), Yoon-Jae CHO (840 United States of America), Uri TABORI (124 Canada), James M. OLSON (840 United States of America), Amar GAJJAR (840 United States of America), RogerJ. PACKER (840 United States of America), Stefan RUTKOWSKI (276 Germany), Scott L. POMEROY (840 United States of America), Pim J. FRENCH (528 Netherlands), Nanne K. KLOOSTERHOF (528 Netherlands), Johan M. KROS (528 Netherlands), Erwin G. VAN MEIR (840 United States of America), Steven C. CLIFFORD (826 United Kingdom of Great Britain and Northern Ireland), Franck BOURDEAUT (250 France), Olivier DELATTRE (250 France), Francois F. DOZ (250 France), Cynthia E. HAWKINS (124 Canada), David MALKIN (124 Canada), Wieslawa A. GRAJKOWSKA (616 Poland), Marta PEREK-POLNIK (616 Poland), Eric BOUFFET (124 Canada), James T. RUTKA (124 Canada), Stefan M. PFISTER (276 Germany) and Michael D. TAYLOR (124 Canada).
Edition Journal of clinical oncology, United States, American Society of Clinical Oncology, 2014, 0732-183X.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30200 3.2 Clinical medicine
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 18.443
RIV identification code RIV/00216224:14110/14:00076105
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1200/JCO.2013.50.9539
UT WoS 000335137900019
Keywords in English NEUROTROPHIN RECEPTOR TRKC; CHILDHOOD MEDULLOBLASTOMA; BRAIN-TUMORS; MOLECULAR SUBGROUPS; RISK STRATIFICATION; PATHWAY ACTIVATION; OUTCOME PREDICTION; MYCN AMPLIFICATION; TP53 MUTATIONS; POOR-PROGNOSIS
Tags EL OK
Tags International impact, Reviewed
Changed by Changed by: Soňa Böhmová, učo 232884. Changed: 24/4/2015 13:11.
Abstract
Purpose Medulloblastoma comprises four distinct molecular subgroups: WNT, SHH, Group 3, and Group 4. Current medulloblastoma protocols stratify patients based on clinical features: patient age, metastatic stage, extent of resection, and histologic variant. Stark prognostic and genetic differences among the four subgroups suggest that subgroup-specific molecular biomarkers could improve patient prognostication. Patients and Methods Molecular biomarkers were identified from a discovery set of 673 medulloblastomas from 43 cities around the world. Combined risk stratification models were designed based on clinical and cytogenetic biomarkers identified by multivariable Cox proportional hazards analyses. Identified biomarkers were tested using fluorescent in situ hybridization (FISH) on a nonoverlapping medulloblastoma tissue microarray (n = 453), with subsequent validation of the risk stratification models. Results Subgroup information improves the predictive accuracy of a multivariable survival model compared with clinical biomarkers alone. Most previously published cytogenetic biomarkers are only prognostic within a single medulloblastoma subgroup. Profiling six FISH biomarkers (GLI2, MYC, chromosome 11 [chr11], chr14, 17p, and 17q) on formalin-fixed paraffin-embedded tissues, we can reliably and reproducibly identify very low-risk and very high-risk patients within SHH, Group 3, and Group 4 medulloblastomas. Conclusion Combining subgroup and cytogenetic biomarkers with established clinical biomarkers substantially improves patient prognostication, even in the context of heterogeneous clinical therapies. The prognostic significance of most molecular biomarkers is restricted to a specific subgroup. We have identified a small panel of cytogenetic biomarkers that reliably identifies very high-risk and very low-risk groups of patients, making it an excellent tool for selecting patients for therapy intensification and therapy de-escalation in future clinical trials.
PrintDisplayed: 25/5/2024 07:42